Aethlon Medical, Inc. (NASDAQ:AEMD) Sees Significant Drop in Short Interest

Aethlon Medical, Inc. (NASDAQ:AEMD) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 187,291 shares, a decline of 43.3% from the May 31st total of 330,345 shares. Based on an average daily trading volume, of 370,446 shares, the short-interest ratio is currently 0.5 days. Approximately 8.0% of the company’s stock are short sold.

Aethlon Medical Stock Down 6.1%

Shares of NASDAQ AEMD opened at $0.71 on Friday. Aethlon Medical has a fifty-two week low of $0.65 and a fifty-two week high of $27.40. The business has a 50 day moving average price of $1.96 and a two-hundred day moving average price of $2.21. The firm has a market cap of $1.68 million, a PE ratio of -0.05 and a beta of 1.41.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent SEC filing. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.